These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 29340789)

  • 1. Fully sialylated alpha-chain of complement 4-binding protein (A2160): a novel prognostic marker for epithelial ovarian carcinoma.
    Matsuo K; Tanabe K; Ikeda M; Shibata T; Kajiwara H; Miyazawa M; Miyazawa M; Hayashi M; Shida M; Hirasawa T; Roman LD; Mikami M
    Arch Gynecol Obstet; 2018 Mar; 297(3):749-756. PubMed ID: 29340789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fully-sialylated alpha-chain of complement 4-binding protein: Diagnostic utility for ovarian clear cell carcinoma.
    Mikami M; Tanabe K; Matsuo K; Miyazaki Y; Miyazawa M; Hayashi M; Asai S; Ikeda M; Shida M; Hirasawa T; Kojima N; Sho R; Iijima S
    Gynecol Oncol; 2015 Dec; 139(3):520-8. PubMed ID: 26477941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
    Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
    J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
    Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of elevated pretreatment serum levels of CEA and CA-125 in epithelial ovarian cancer.
    Lin YH; Wu CH; Fu HC; Chen YJ; Chen YY; Ou YC; Lin H
    Cancer Biomark; 2020; 28(3):285-292. PubMed ID: 32390605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response.
    Zorzato PC; Zannoni GF; Tudisco R; Pasciuto T; Di Giorgio A; Franchi M; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2020 Jan; 30(1):67-73. PubMed ID: 31754067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of serum HE4 as a prognostic marker in carcinoma of the ovary.
    Lakshmanan M; Kumar V; Chaturvedi A; Misra S; Gupta S; Akhtar N; Rajan S; Jain K; Garg S
    Indian J Cancer; 2019; 56(3):216-221. PubMed ID: 31389384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative change in CA125 is an independent prognostic factor for improved clinical outcome in advanced ovarian cancer.
    Timmermans M; Zwakman N; Sonke GS; Van de Vijver KK; Duk MJ; van der Aa MA; Kruitwagen RF
    Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():364-369. PubMed ID: 31400565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-operative prediction of residual disease after interval cytoreduction for epithelial ovarian cancer using HE4.
    Lof P; van de Vrie R; Korse CM; van Driel WJ; van Gent MDJM; Karlsen MA; Amant F; Lok CAR
    Int J Gynecol Cancer; 2019 Oct; 29(8):1304-1310. PubMed ID: 31515411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.
    Feng LY; Liao SB; Li L
    J Ovarian Res; 2020 Feb; 13(1):17. PubMed ID: 32050995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma.
    Matsuo K; Wong KK; Fotopoulou C; Blake EA; Robertson SE; Pejovic T; Frimer M; Pardeshi V; Hu W; Choi JS; Sun CC; Richmond AM; Marcus JZ; Hilliard MAM; Mostofizadeh S; Mhawech-Fauceglia P; Abdulfatah E; Post MD; Saglam O; Shahzad MMK; Karabakhtsian RG; Ali-Fehmi R; Gabra H; Roman LD; Sood AK; Gershenson DM
    J Surg Oncol; 2018 Feb; 117(2):236-244. PubMed ID: 28787528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.
    Zwakman N; van de Laar R; Van Gorp T; Zusterzeel PL; Snijders MP; Ferreira I; Massuger LF; Kruitwagen RF
    J Gynecol Oncol; 2017 Jan; 28(1):e7. PubMed ID: 27670261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of CA-125 re-elevation after interval debulking surgery in patients with advanced-stage ovarian cancer undergoing neoadjuvant chemotherapy.
    Lee YJ; Chung YS; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
    Eur J Surg Oncol; 2019 Apr; 45(4):644-649. PubMed ID: 30337203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of the controlling nutritional status (CONUT) score in epithelial ovarian cancer.
    Li Y; Zhang C; Ji R; Lu H; Zhang W; Li LL; Liu R; Qian H; He A
    Int J Gynecol Cancer; 2020 Jan; 30(1):74-82. PubMed ID: 31822507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [CA 125 regression after two cycles of neoadjuvant chemotherapy as prognostic factor in patients with advanced ovarian cancer and primary peritoneal serous cancer who underwent interval surgical cytoreduction].
    Gasowska-Bodnar A; Bodnar L; Wcisło GB; Jerzak MM; Szczylik C; Baranowski W
    Ginekol Pol; 2008 Feb; 79(2):108-14. PubMed ID: 18510089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
    Shen Y; Li L
    Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of Percent Reduction in CA-125 Levels on Prediction of the Extent of Interval Cytoreduction and Outcome in Patients With Advanced-Stage Cancer of Müllerian Origin Treated With Neoadjuvant Chemotherapy.
    Mahdi H; Maurer KA; Nutter B; Rose PG
    Int J Gynecol Cancer; 2015 Jun; 25(5):823-9. PubMed ID: 25828750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
    Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
    Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.
    Gockley AA; Fiascone S; Hicks Courant K; Pepin K; Del Carmen M; Clark RM; Goldberg J; Horowitz N; Berkowitz R; Worley M
    Int J Gynecol Cancer; 2019 Mar; 29(3):585-592. PubMed ID: 30833444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.